Brookline Capital Management Reaffirms Hold Rating for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS)‘s stock had its “hold” rating restated by analysts at Brookline Capital Management in a research report issued on Wednesday, MarketBeat.com reports.

A number of other equities research analysts have also issued reports on SYRS. HC Wainwright reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. StockNews.com lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Trading Down 23.4 %

SYRS stock opened at $0.28 on Wednesday. The firm’s fifty day simple moving average is $2.04 and its two-hundred day simple moving average is $3.81. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the company earned ($1.35) EPS. Analysts predict that Syros Pharmaceuticals will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CFO Jason Haas bought 35,363 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $1.55 per share, with a total value of $54,812.65. Following the transaction, the chief financial officer now directly owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. This represents a 144.03 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Conley Chee purchased 50,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was acquired at an average cost of $1.51 per share, with a total value of $75,500.00. Following the acquisition, the chief executive officer now owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. This represents a 222.18 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 130,707 shares of company stock valued at $206,491. 12.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SYRS. Opaleye Management Inc. lifted its stake in shares of Syros Pharmaceuticals by 119.1% during the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after buying an additional 428,175 shares during the period. Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter worth about $2,166,000. Vanguard Group Inc. lifted its position in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares during the period. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the 2nd quarter valued at about $109,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.